Company Overview and News

Fitch affirms HNB Assurance and HNB General Insurance ratings

2018-03-19 lankabusinessonline
Fitch Ratings Lanka has affirmed Sri Lanka-based HNB Assurance PLC’s (HNBA) National Insurer Financial Strength (IFS) Rating and National Long-Term Rating of ‘A(lka)’. Fitch has also affirmed its 100% owned subsidiary HNB General Insurance Limited’s (HNBGI) National IFS Rating and National Long-Term Rating at ‘A(lka)’. The Outlook on the ratings is Stable.

Grand finale of CA Sri Lanka 53rd Annual Report Awards Competition

2017-12-06 lankabusinessonline
Commercial Bank of Ceylon PLC won the coveted ‘Cyril Gardiner Memorial Trophy’ Gold Award for Overall Excellence in Annual Financial Reporting at the grand finale of the 53rd Annual Report Awards Competition organized by the Institute of Chartered Accountants of Sri Lanka (CA Sri Lanka).

Thimal Perera appointed as new Deputy CEO of DFCC Bank

2017-08-16 lankabusinessonline
DFCC Bank PLC announced the appointment of Thimal Perera as the Bank’s new Deputy CEO, with effect from 16 August 2017.

HNB emerges as most profitable private banking group with Rs22.5bn PBT

2017-02-27 lankabusinessonline
An outstanding performance throughout 2016 on every front culminated in the HNB Group posting the best financial results in its history. Group Profit Before VAT, NBT and Taxes grew by 41.3% to Rs 27.1 Bn while Profit Before Tax (PBT) reached Rs 22.5 Bn with a 39.2% growth. Group Profit After Tax (PAT) witnessed an exceptional growth of 41.2% to be recorded at Rs 15.7 Bn. Group assets grew by 19.0% to cross the Rs 900 Bn mark, representing yet another historical milestone for HNB.

Sri Lanka’s HNB net up 41-pct in June quarter amid income growth

2016-08-11 lankabusinessonline
Aug 11, 2016 (LBO) – Group profits at Sri Lanka’s Hatton National Bank surged 41 percent to 3.3 billion rupees in the June 2016 quarter from a year earlier amid strong income growth, interim accounts showed.

HNB sets new benchmark in private banking

~ ‘HNB Priority Circle’ offers a host of benefits and advisory services to meet the needs of discerning customers

HNB sets new benchmark in Private banking

‘HNB Priority Circle’ offers a host of benefits and advisory services to meet the needs of discerning customers By offering a gamut of personalised advisory services, from investments to travel – in addition to other personalized services enjoyed by customers, Hatton National Bank (HNB) PLC is seeking to set a new benchmark in terms of customer convenience in the country’s high net-worth domain.

Maj. Gen. Upul Perera reappointed IMSL President for 2016/17 at 38th AGM

The 38th Annual General Meeting of Institute of Management of Sri Lanka (IMSL) was held recently (23rd June 2016), which saw the reappointment of Maj. Gen. Upul Perera as the President of IMSL for 2016/17. The Council of Management of IMSL for this period was also unanimously appointed at the meeting which took place at Hotel Galadari Colombo.

Sri Lanka’s HNB net up 73-pct in March 2016 quarter

2016-05-10 lankabusinessonline
May 10, 2016 (LBO) – Group profits at Sri Lanka’s Hatton National Bank surged 73 percent to 3.3 billion rupees in the March 2016 quarter amid strong income growth, interim accounts showed.

HNB Grameen shares to be listed in CSE

2016-01-06 lankabusinessonline
Jan 06, 2016 (LBO) – Hatton National Bank’s micro finance arm, HNB Grameen is to list its shares in the Colombo Stock Exchange shortly, Managing Director of HNB, Jonathan Alles said. Alles was spea...

Related Articles

SGMO: Sangamo BioSciences and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...